Health Care & Life Sciences » Pharmaceuticals | Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
137.00
31,986.00
23,001.00
15,448.00
18,997.00
90,188
Total Accounts Receivable
11.00
64.00
109.00
284.00
155.00
218
Other Current Assets
5.00
101.00
270.00
-
-
-
Total Current Assets
153.00
32,151.00
23,380.00
15,732.00
19,152.00
90,406
Net Property, Plant & Equipment
13.00
774.00
883.00
718.00
491.00
194
Total Assets
166.00
32,925.00
24,263.00
16,450.00
19,643.00
90,600
Accounts Payable
-
-
-
3,122.00
2,276.00
Other Current Liabilities
1,689.00
1,118.00
2,541.00
1,457.00
1,572.00
Total Current Liabilities
1,689.00
1,118.00
2,541.00
4,579.00
3,848.00
Other Liabilities
428.00
400.00
177.00
796.00
-
Total Liabilities
2,117.00
1,518.00
2,718.00
5,375.00
3,848.00
Common Equity (Total)
1,951.00
31,407.00
21,545.00
11,075.00
15,795.00
Total Shareholders' Equity
1,951.00
31,407.00
21,545.00
11,075.00
15,795.00
Total Equity
1,951.00
31,407.00
21,545.00
11,075.00
15,795.00
Liabilities & Shareholders' Equity
166.00
32,925.00
24,263.00
16,450.00
19,643.00

About Galmed Pharmaceuticals

View Profile
Address
16 Zeev Tiomkin Street
Tel Aviv TA 6578317
Israel
Employees -
Website http://www.galmedpharma.com
Updated 07/08/2019
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.